Background: Mdm-2, a zinc finger protein, negatively regulates the p53 tumor suppressor gene product by binding to it and preventing transcriptional activation (16). Materials and Methods: Assays for p53 mediated transcription, repression and activation by mutant and wild-type p53 proteins were used to measure the ability of mdm-2 to block each activity. Results: Mdm-2 was able to inhibit all three functions of the wild-type and mutant p53 activities; transcriptional activation by the wild-type protein, transcriptional activation by the mutant p53 protein, and repression by the wild-type protein.
INTRODUCTION
The p53 tumor suppressor gene and its protein product have been shown to be involved as a checkpoint in the cell cycle in response to DNA damage (1) (2) (3) . The p53 protein is a transcription factor that can regulate a set of genes resulting in cell cycle growth arrest (1) (2) (3) or apoptosis (4, 5) . Transcriptional activation of genes by the p53 protein requires an amino-terminal transcription activation domain and a DNA sequence-specific DNA binding domain. The mutant p53 proteins from human cancer cells have lost transcription factor activity (6) (7) (8) , suggesting that this activity plays a critical role in the tumor suppressor function of p53. The wild-type p53 protein has also been shown to repress or negatively regulate transcription from a variety of viral and cellular promoters that do not contain DNA sequences recognized by the p53 protein (9) (10) (11) (12) . Finally, some mutant p53 proteins, but not the wild-type protein, can transcriptionally activate the multidrug resistance gene-1 promoter (MDR-1) in transient transfection assays ( 13) and this reflects a "gain of function" phenotype of mutant p53 proteins (14, 15) .
Recently, p53 has been shown to bind to a cellular protein encoded by the mdm-2 oncogene (16) . The mdm-2 gene was originally isolated as a cellular oncogene amplified on a mouse double-minute chromosome. Overexpression of the mdm-2 gene in BALB/c 3T3 cells increased their tumorigenic potential (17) . The murine mdm-2 genomic clone can transform primary rat embryo fibroblasts in cooperation with the activated ras oncogene (18) . Overexpression of the mdm-2 gene also inhibits transcription 143 activation by p53 (16) . Furthermore, amplification of the mdm-2 gene has been observed in several types of human sarcomas (19, 20) . The mdm-2 gene can be positively regulated by the p53 protein through a p53-responsive DNA element present in its first intron (21, 22) . This then provides a way to regulate the level of p53 activity via a negative feedback loop (22) . Mdm-2 binds to the N-terminal 52 residues of p53 which contain the transactivation domain (23, 24) . Based upon this, it was proposed that mdm-2 may suppress p53-mediated transcription by blocking its transactivation domain. Thus, the transforming activity of mdm-2 could result from the inhibition of the transactivation activity of p53.
The strong physical association between mdm-2 and p53 suggests that complex formation may be important for the functional interaction between the two proteins. In some experimental systems such as the tumorigenic DM3T3 cell line, where p53 is apparently suppressed by the overexpressed mdm-2 gene, the majority of the p53 protein in the cell is indeed present in a complex with mdm-2 (25). However, there has not always been strict correlation between the detection of the p53-mdm-2 complex and the suppression of p53 function in other systems (18, 26) . Therefore, it is not clear whether formation of a detectable complex is necessary for the inhibition of p53 function. The polypeptide sequence of mdm-2 contains a central acidic region and three zinc-finger motifs, suggestive of a role as a transcription factor. These highly conserved domains are dispensable for the binding to p53 protein in vitro (23) but they still could encode functions that contribute to or indirectly regulate p53 function. For this reason, a study was initiated to identify the functional domains of the mdm-2 protein that play a role in regulating several of the p53 transcriptional activities.
This report describes the evidence demonstrating that mdm-2 can negatively regulate the wild-type p53 protein activities for transcriptional activation and transcriptional repression. The mdm-2 protein also eliminates the ability of mutant p53 proteins to transactivate the MDR-1 promoter in cells. A panel of mdm-2 mutant proteins was used to demonstrate that binding to the p53 protein by the amino-terminal residues of mdm-2 was sufficient to regulate all of these activities of the p53 protein. Furthermore, p53 point mutations that specifically destroyed the binding of mdm-2 to p53 were employed to demonstrate the critical role of the physical interaction between mdm-2 and p53 in the regulation of the p53 transcriptional activity.
MATERIALS AND METHODS

Plasmids
Human mdm-2 deletion mutants A222-325 and A222-437 were constructed by PCR amplification of the mdm-2 coding regions between 325 and 491, and 437 and 491 using the following primers: 5'-CGGGATCCCCTTCGTGAGAATTGGC -3' for A222-325 and 5'-CGGGATCCTTGTGT GA1TTGTCAA-3' for A222-437. After amplification, the PCR products were digested with BamHI and inserted into a Bluescript plasmid encoding residues 1-222 of mdm-2. The p53 binding activities of these two mutants in vitro were determined as previously described (23 (Fig. 3A) . The inhibition by the mdm-2 cDNA was reversed when greater amounts of the p53 expression plasmid was used, suggesting that excess p53 expression will overcome the limited amount of mdm-2 protein produced by the expression vector.
Next, the entire panel of mdm-2 deletion mutants was utilized to identify the regions of the mdm-2 protein that were necessary for regulation of p53. The results, shown in Fig. 3B , show that the mdm-2 mutants that bind to the p53 protein and have an intact NLS region are all able to inhibit p53-mediated transactivation. Those mdm-2 mutant proteins that do not bind to p53 protein do not inhibit its activity. These data demonstrate that the central acidic region and the carboxyl zinc-finger motifs of the mdm-2 protein are dispensable for inhibition of p53 mediated transactivation. Therefore, the region of the mdm-2 protein that is essential for in vivo inhibition of wild-type p53-mediated transactivation is included in the N-terminal 222 amino acid residues. The ability of the deletion mutants to bind to p53 and localize to the nucleus appear to be essential for the inhibition of p53 mediated transactivation. Fig. 5 , mutant p53 175Arg-His and 281Asp-Gly activated MDR-CAT in a dosedependent fashion up to 30-to 40-fold in the SAOS-2 cells. This activation was not significantly affected by cotransfection with the mdm-2 deletion mutant (A59-89) defective in its interaction with the p53 protein. However, transfection with a wild-type mdm-2 plasmid or a mdm-2 deletion mutant (A222-437) still capable of binding to p53 protein, resulted in significant inhibition of CAT expression (more than 10-fold reduction for mutant 175 and approximately 5-fold reduction for mutant 281). Similarly, mutants A340-491 and A440-491 can bind to mutant p53 in vitro and were able to inhibit mutant p53 (data not shown). Therefore, the transactivation of the MDR promoter by mutant mdm-2 is also negatively regulated by mdm-2. The effect of mdm-2 in this assay is specific for the p53-mediated activation by a p53 mutant protein because the activation of the MDR-1 promoter, using an activated ras oncogene, was not affected by mdm-2 (data not shown). Thus, the ras activation of MDR-1 is not mediated through a mutant p53 pathway.
Relief of p53-Mediated Repression by mdm-2 Protein
The efficient inhibition of p53-mediated transactivation by mdm-2 in transient transfection assays led us to further test the ability of mdm-2 in the regulation of another p53-mediated activity, transcriptional repression of a test gene. Two reporter constructs were utilized for this experiment; pRSV-CAT contains the CAT gene driven by the Rous sarcoma virus long terminal repeat (32) , and the second plasmid pSTi-CAT contains several SP1 binding sites, the adenovirus major late promoter TATA box, and the TDT initiator DNA sequences. Consistent with previous reports, the pRSV-CAT expression vector was repressed 10-to 20-fold by wild-type p53 protein (Fig. 6) . Cotransfection of pSTi-CAT with a wildtype p53 plasmid also resulted in a 5-to 10-fold reduction of CAT activities (Fig. 6) . Cotransfection with a third plasmid, the CMV-neo vector, as well as plasmids encoding mdm-2 mutants Al-50 and A59-89 which are defective for p53 binding, had no effect on the repression of these reporter genes by p53 proteins. However, when a full-length mdm-2 expression plasmid or two mdm-2 mutants (A440-491 and A222-437) that are able to bind to p53 proteins were cotransfected, there was a significant relief of the p53-mediated repression over the entire range of the titration curve. The inhibition of repression by mdm-2 is most evident when lower levels of the p53 plasmids were used. The relief of repression by mdm-2 was observed with both the RSV-CAT and the pSTi-CAT reporter plasmids. These results demonstrate that the mdm-2 protein can block transcriptional repression by the p53 protein and this also requires direct binding between the two proteins.
DISCUSSION
The wild-type p53 protein can positively transactivate the transcription of genes that contain p53-DNA binding responsive elements and negatively represses many genes without such elements (9) (10) (11) (12) (33) (34) (35) (36) . The positive regulation of the p21-pic-1 (or WAF-1) gene is thought to mediate the G1 arrest of cells expressing high levels of p53 protein (1, 2, (37) (38) (39) . The p21 gene product binds to the cyclin dependent kinase-2 and inhibits its activity, thus blocking progress through the cell cycle (40, 41) . While a direct role for transcriptional repression in these processes has not been proven, it has been suggested that p53-mediated transcriptional repression plays a role in initiating apoptosis (42) in a p53-dependent fashion. Mdm-2 will inhibit both positive and negative regulation of transcription by the wild-type p53 protein (Fig. 7) . The third activity of the p53 protein tested here is the ability of mutant p53 proteins to transcriptionally activate the MDR-1 promoter in cells (13, 15, 43) . This is a novel function associated only with mutant forms of p53 protein, but not the wild-type protein, and mdm-2 protein also blocks the ability of mutant p53 to activate the MDR-1 promoter (Fig. 7) . For all of these activities of the mdm-2 protein, the amino terminal domain between residues 1 (16) (17) (18) (19) (20) . Mdm-2 plus an activated ras oncogene can transform primary rat embryo fibroblasts (18) . Overexpression of mdm-2 can block the ability of wild-type p53 to suppress transformation of cells in culture (18) . The mdm-2 genes are amplified and overexpressed in several types of sarcomas (19, 20) , and overexpression of the mdm-2 has been shown to enhance the tumorigenic potential of cells in nude mice (17) . Mdm-2 could act as an oncogene product solely by inhibiting p53 functions or it could also have activities intrinsic to the mdm-2 protein regions not involved in p53 regulation. The fact that amino acid residues 222-491, which encode an acidic domain and the zinc-fingers of the protein, are dispensable for blocking p53 functions suggests additional mdm-2 functions that reside in those domains. In addition, there are several isoforms of mdm-2 proteins in a cell (25) , and at least one isoform lacks the amino-terminal epitopes required for mdm-2 to bind to p53 (25) . The presence of mdm-2 proteins that fail to bind to p53 also suggests additional functions for mdm-2 in light of the clear requirement for mdm-2 to bind to p53 for it to block p53-mediated functions.
The amino-terminal domain of the p53 protein is required for transcriptional transactivation probably by interacting with the basal transcription factors in a cell (7) . Amino acid residues 22 and 23 of the p53 protein appear to play a critical role in this process (29) . The mdm-2 protein binds to amino acids 22 and 23 as part of its binding site on the p53 protein, and so it had been suggested that mdm-2 functions by sterically blocking the interaction of p53 with the basal transcriptional machinery (23, 24) . The fact that mdm-2 must bind to the p53 protein to inhibit its activities, as shown here, supports that hypothesis. An additional test of this hypothesis is that the mutations at amino acid residues 22 and 23 should destroy the ability of a mutant p53 protein to activate the MDR-1 promoter, just as mdm-2 blocks this activity. This is indeed the case. The p53 22Leu-Gln and 23Trp-Ser mutants are defective for MDR-1 transactivation when they are combined with a 281 p53 mutant protein (J. Lin and A. J. Levine, in preparation). The fact that these predictions are borne out in these experimental tests is most consistent with the idea that mdm-2 sterically blocks p53 interaction .
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!I-with basal transcription factors. The more complicated hypothosis, that mdm-2 has in its first 222 residues an active repression domain, as was proposed for the adenovirus EIB-S5kD-p53 complex (44) , remains a formal alternative that will now need to be tested.
